These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 18313445)

  • 1. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.
    Barr E; Gause CK; Bautista OM; Railkar RA; Lupinacci LC; Insinga RP; Sings HL; Haupt RM
    Am J Obstet Gynecol; 2008 Mar; 198(3):261.e1-11. PubMed ID: 18313445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.
    Paavonen J;
    Curr Med Res Opin; 2008 Jun; 24(6):1623-34. PubMed ID: 18435868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quadrivalent human papillomavirus vaccine.
    Barr E; Tamms G
    Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
    Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
    N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
    Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
    J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
    Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E
    J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and incidence of HPV genital infection in women.
    Velicer C; Zhu X; Vuocolo S; Liaw KL; Saah A
    Sex Transm Dis; 2009 Nov; 36(11):696-703. PubMed ID: 19652630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccines for preventing HPV-related anogenital infection and neoplasia.
    Ferris DG
    J Am Osteopath Assoc; 2006 Mar; 106(3 Suppl 1):S9-13. PubMed ID: 16729555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.
    Barthell E; Woelber L; Hellner K; Camerer B; Gieseking F; Hauschild M; Mylonas I; Friese K; Sings HL; Railkar R; Gause C; Barr E
    Arch Gynecol Obstet; 2009 Jun; 279(6):803-7. PubMed ID: 18936950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
    Villa LL
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention strategies against the human papillomavirus: the effectiveness of vaccination.
    Stanley M
    Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S19-23. PubMed ID: 17938013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review.
    Ault KA
    Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S26-31. PubMed ID: 16729901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
    Dunne EF; Datta SD; E Markowitz L
    Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protecting our patients from HPV and HPV-related diseases: the role of vaccines.
    Mahoney MC
    J Fam Pract; 2006 Nov; Suppl():10-7. PubMed ID: 17366753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New quadrivalent HPV vaccine developments.
    Tovar JM; Bazaldua OV
    Postgrad Med; 2008 Nov; 120(4):14-6. PubMed ID: 19020361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV vaccination - a paradigm shift in public health.
    May J
    Aust Fam Physician; 2007 Mar; 36(3):106-11. PubMed ID: 17339969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HPV vaccination: principles, results and future perspectives].
    Rouzier R; Uzan C; Collinet P
    J Gynecol Obstet Biol Reprod (Paris); 2007 Feb; 36(1):13-8. PubMed ID: 17293248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy.
    Lehtinen M; Idänpään-Heikkilä I; Lunnas T; Palmroth J; Barr E; Cacciatore R; Isaksson R; Kekki M; Koskela P; Kosunen E; Kuortti M; Lahti L; Liljamo T; Luostarinen T; Apter D; Pukkala E; Paavonen J
    Int J STD AIDS; 2006 Apr; 17(4):237-46. PubMed ID: 16595046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Knowledge of HPV-related genital lesions and of anti-HPV vaccination in a sample of women of north-eastern Italy].
    Sopracordevole F; Cigolot F; Lucia E; Marchesoni D
    Minerva Ginecol; 2009 Apr; 61(2):81-7. PubMed ID: 19255555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.